fashion -WSS

fashion

author：hotspot 2025-09-02 08:18:30 - browse：2459

Jakub Porzycki/NurPhoto via AP

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the fallout from Pfizer’s downbeat update, a new entrant in obesity research, and an orthogonal CRISPR business.

The need-to-know this morning

Apellis Pharmaceuticals said a European advisory committee is expected to recommend against the approval of Syfovre, its eye drug for a common form of blindness. The company plans to appeal the negative ruling.
Sage Therapeutics and Biogen announced the commercial launch of Zurzuvae, an oral treatment for women with postpartum depression.
Merck and Moderna reported three-year follow-up data on their mRNA-based immunotherapy for advanced melanoma. Phase 3 studies are underway.
The FDA accepted Amgen’s marketing application for tarlatamab, a bispecific antibody to treat advanced small cell lung cancer. The approval decision date is June 12, 2024.

Is it time to worry about Moderna?

Yesterday’s news that Pfizer is expecting to sell far fewer Covid-19 vaccines than Wall Street expected sent shares of Moderna down as much as 6% on fears that the company could be in for a painful revision of its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： ALS advocates say criticism of new drugs misses bigger picture

WSS

Ethical issues complicate the benefits of medical crowdfunding

Trump surgeon general acknowledges mistakes during Covid

Europe sees delivery challenges ahead on Alzheimer's therapies

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Celiac disease study examines precisely how gluten triggers injury

Amazon on where the company's health care bets are headed next

focus

fashion

The need-to-know this morning

Is it time to worry about Moderna?

leisure time

How to save PrEP access — and even expand it

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Hollywood unions extend contract negotiations for actors

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

The cancer drug shortage isn’t new — and neither are the solutions

How to protect patients from sexual assault

As demand for Covid shots wanes, Moderna seeks its next success

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Peter Hotez and the public health issue of online harassment

The (many) problems with a new study criticizing cancer screening

hotspot

ALS advocates say criticism of new drugs misses bigger picture

Advances in CAR

AstraZeneca chief proposes a novel edit to the drug pricing bill

NIH nominee Bertagnolli will get October confirmation hearing

Does aspartame cause cancer? What new WHO guidance says

Global childhood vaccinations edge closer to pre

knowledge

hotspot

explore

knowledge